Related references
Note: Only part of the references are listed.Genetic Modification of the O-Polysaccharide of Francisella tularensis Results in an Avirulent Live Attenuated Vaccine
Tae-Hyun Kim et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Recent developments in bacterial protein glycan coupling technology and glycoconjugate vaccine design
Vanessa S. Terra et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2012)
Exploiting the Campylobacter jejuni protein glycosylation system for glycoengineering vaccines and diagnostic tools directed against brucellosis
Jeremy A. Iwashkiw et al.
MICROBIAL CELL FACTORIES (2012)
Prevnar 13, the New 13-Valent Pneumococcal Conjugate Vaccine
Allana J. Sucher et al.
ANNALS OF PHARMACOTHERAPY (2011)
Francisella tularensis: A Red-blooded Pathogen
J. Wayne Conlan
JOURNAL OF INFECTIOUS DISEASES (2011)
Production of glycoprotein vaccines in Escherichia coli
Julian Ihssen et al.
MICROBIAL CELL FACTORIES (2010)
N-linked glycosylation in bacteria: an unexpected application
Rebecca H. Langdon et al.
FUTURE MICROBIOLOGY (2009)
Antigen- specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge
Leah E. Cole et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis
Shite Sebastian et al.
VACCINE (2009)
Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS)
J. E. Eyles et al.
MICROBIAL PATHOGENESIS (2008)
Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like pailicle vaccine containing AS04 adjuvant
Court Pedersen et al.
JOURNAL OF ADOLESCENT HEALTH (2007)
Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis
Carlos G. Grijalva et al.
LANCET (2007)
N-linked glycosylation of folded proteins by the bacterial oligosaccharyltransferase
Michael Kowarik et al.
SCIENCE (2006)
Definition of the bacterial N-glycosylation site consensus sequence
Michael Kowarik et al.
EMBO JOURNAL (2006)
Substrate specificity of bacterial oligosaccharyltransferase suggests a common transfer mechanism for the bacterial and eukaryotic systems
M Wacker et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli
MF Feldman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Tularaemia:: Bioterrorism defence renews interest in Francisella tularensis
PCF Oyston et al.
NATURE REVIEWS MICROBIOLOGY (2004)
Evaluation of lipopolysaccharide and capsular polysaccharide as subunit vaccines against experimental melioidosis
M Nelson et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2004)
Genetic and physical map of the pLAFR1 vector
E Vanbleu et al.
DNA SEQUENCE (2004)
Immunology of bacterial polysaccharide antigens
A Weintraub
CARBOHYDRATE RESEARCH (2003)
Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp tularensis
JL Prior et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2003)
N-linked glycosylation in Campylobacter jejuni and its functional transfer into E-coli
M Wacker et al.
SCIENCE (2002)
Structure of the N-linked glycan present on multiple glycoproteins in the gram-negative bacterium, Campylobacter jejuni
NM Young et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Mice vaccinated with the O-antigen of Francisella tularensis LVS lipopolysaccharide conjugated to bovine serum albumin develop varying degrees of protective immunity against systemic or aerosol challenge with virulent type A and type B strains of the pathogen
JW Conlan et al.
VACCINE (2002)
Tularemia outbreak investigation in Kosovo: Case control and environmental studies
R Reintjes et al.
EMERGING INFECTIOUS DISEASES (2002)
Role of antibody to lipopolysaccharide in protection against low- and high-virulence strains of Francisella tularensis
M Fulop et al.
VACCINE (2001)
Tularemia as a biological weapon - Medical and public health management
DT Dennis et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Share Paper
